Entera Bio Phase 2 Data Supporting EB613’s (Oral PTH(1-34)) Anabolic Effect on Postmenopausal Women with Osteoporosis at High Risk for Fracture Selected for Plenary Poster Session Presentation at th

Go back to Entera Bio Phase 2 Data Supporting EB613’s (Oral PTH(1-34)) Anabolic Effect on Postmenopausal Women with Osteoporosis at High Risk for Fracture Selected for Plenary Poster Session Presentation at th
Entrx Corporation (NASDAQ: ENTX) Delayed: 3.05 +0.03 (0.99%)
Previous Close $3.02    52 Week High $0.30 
Open $3.12    52 Week Low $0.10 
Day High $3.20    P/E N/A 
Day Low $2.96    EPS $0.00 
Volume 784,598